azilsartan + rosuvastatin

Azilsartan + rosuvastatin is a fixed-dose combination of two pharmaceutical agents used primarily for the management of hypertension and dyslipidemia. Azilsartan is an angiotensin II receptor blocker (ARB) that selectively binds to AT1 receptors, thereby inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to reduced blood pressure[6]. Rosuvastatin is a statin (HMG-CoA reductase inhibitor) that lowers cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme responsible for converting HMG-CoA to mevalonate in cholesterol biosynthesis. This results in decreased LDL-cholesterol and triglycerides, increased HDL-cholesterol, and overall reduction in cardiovascular risk[2][3][8]. The combination targets both elevated blood pressure and abnormal lipid profiles, addressing two major cardiovascular risk factors.

Brand names

Edarbi-Ro

Other names

azilsartan medoxomil + rosuvastatin calciumCTL0801 + CTL0802